ClinicalTrials.gg
CompletedNCT01243424Updated Jan 7, 2020Results posted

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

A Phase 3 interventional study of linagliptin and glimepiride in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 613 sites in 43 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,103
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
2nd of 67
6,103 · median 175
Started
2010
with 7 others
Phase 3
31 of 67
none open now
Registered
24th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 24th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetes
  2. Elevated glycosylated (): 6.5 - 8.5%, inclusive, if treatment naïve or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 - 7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with metformin OR an alpha-glucosidase inhibitor) therapy)
  3. Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age => 70 years OR two or more specified cardiovascular risk factor
  4. =\< 45kg/m²
  5. age between >= 40 and =\< 85 years
  6. signed and dated written International Conference of Harmonisation( ICF)
  7. stable anti-diabetic background for at least 8 wks before study start

Exclusion criteria

Exclusion criteria:

  1. Type 1 diabetes
  2. Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV) inhibitors or any insulin) prior to (previous short term use of insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)
  3. treatment with any anti-obesity drug less than 3 months before ICF
  4. uncontrolled hyperglycemia
  5. previous or planned bariatric surgery or intervention
  6. current or planned system corticoid treatment
  7. change in thyroid hormones treatment
  8. acute liver disease or impaired hepatic function
  9. pre-planned coronary artery revascularization within 6 months of ICF
  10. known to any of the components
  11. Inappropriateness of glimepiride treatment for renal safety issues according to local prescribing information
  12. congestive heart failure class III or IV
  13. acute or chronic metabolic acidosis
  14. hereditary galactose intolerance
  15. alcohol or drug abuse
  16. participation in another trail with IMP given 2 months before Medicinal/Medical Product (IMP) start
  17. pre-menopausal women who are nursing or pregnant or of and not willing to use acceptable method of
  18. patients considered reliable by the investigator
  19. acute coronary syndrome =\< 6 wks before ICF
  20. stroke or (TIA) =\< 3 months prior to ICF
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,103 participants (actual)

Study arms

  • Experimental
    linagliptin

    patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)

    Drug: linagliptin · Drug: glimepiride placebo

  • Active comparator
    glimepiride 1-4 mg QD

    patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)

    Drug: glimepiride · Drug: linagliptin placebo

Interventions

  • linagliptin tablets 5mg QD

  • glimepiride over-encapsulated tablet 1-4 mg QD

  • Druglinagliptin placebo

    linagliptin placebo

  • Drugglimepiride placebo

    glimepiride placebo

06

What researchers measure

Primary outcomes

  1. The First 3-point Major Adverse Cardiovascular Events (3P-MACE)

    The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.

    Time frame: From randomization until individual day of trial completion, up to 432 weeks

Secondary outcomes

  1. The First 4-point (4P)- MACE

    The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.

    Time frame: From randomization until individual day of trial completion, up to 432 weeks

  2. Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase

    The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without \>2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.

    Time frame: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

  3. Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase

    The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without \>2% weight gain during maintenance phase.

    Time frame: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

  4. Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE

    Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.

    Time frame: From randomization until individual day of trial completion, up to 432 weeks

  5. Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE

    Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.

    Time frame: From randomization until individual day of trial completion, up to 432 weeks

  6. Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

    Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * TIA * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)

    Time frame: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

  7. Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

    Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * Transient ischaemic attack (TIA) * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)

    Time frame: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

  8. Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)

    Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  9. Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)

    Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  10. Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol

    Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  11. Change From Baseline to Final Visit in Triglycerides

    Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  12. Change From Baseline to Final Visit in Creatinine

    Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  13. Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)

    Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  14. Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)

    Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.

    Time frame: Baseline and week 432

  15. Percentage of Participants With Transition in Albuminuria Classes

    Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.

    Time frame: Baseline and week 432

  16. Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks

    The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.

    Time frame: Baseline and week 208

  17. Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up

    Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.

    Time frame: 433 weeks

  18. Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study

    Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.

    Time frame: Baseline

  19. CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study

    Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.

    Time frame: Baseline

07

Results

Posted Jan 7, 2020

Participant flow

This multicentre, multinational, randomised, double-blind, double-dummy, parallel group,comparator-controlled trial compared Linagliptin versus (vs.) Glimepiride, predominantly on metformin background treatment in participants with type 2 diabetes mellitus (T2DM) at elevated cardiovascular (CV) risk receiving usual care.

Discontinuation From Study (Treated Set)
Participant flow — Discontinuation From Study (Treated Set)
MilestoneLinagliptinGlimepiride
Started30283014
Patient died (other cause than cv death)123146
Treated30233010
Completed28992895
Not completed129119
Withdrew: Consent withdrawn (status alive)4937
Withdrew: Consent withdrawn (status unknown)1412
Withdrew: Site closure (status alive)1522
Withdrew: Site closure (status unknown)01
Withdrew: Losttofollowupfor3p-mace(statusalive)3835
Withdrew: Losttofollowupfor3p-mace(statusunknown)88
Withdrew: Not treated54
Discontinuation From Treatment
Participant flow — Discontinuation From Treatment
MilestoneLinagliptinGlimepiride
Started30283014
Treated30233010
Completed18961832
Not completed11321182
Withdrew: Not treated54
Withdrew: Adverse event457523
Withdrew: Lack of efficacy6141
Withdrew: Protocol violation4647
Withdrew: Lost to follow-up2428
Withdrew: Withdrawal by subject309328
Withdrew: Other than listed above230211

Outcome measures

PrimaryThe First 3-point Major Adverse Cardiovascular Events (3P-MACE)

The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.

Time frame:
From randomization until individual day of trial completion, up to 432 weeks
Reported as:
Number · Events/ 1000 patients-years
The First 3-point Major Adverse Cardiovascular Events (3P-MACE)
Events/ 1000 patients-yearsLinagliptinGlimepiride
The First 3-point Major Adverse Cardiovascular Events (3P-MACE)20.721.2
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Cox · p = <0.0001 (P-values derived from Wald´s Chi-square test for non-inferiority were calculated.) · Hazard ratio (hr): 0.98 · 95.47% CI 0.84 to 1.14Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride
  • Linagliptin vs Glimepiride · Regression, Cox · p = 0.3813 (P-values derived from Wald´s Chi-square test.) · Hazard ratio (hr): 0.98 · 95.47% CI 0.84 to 1.14Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride.
SecondaryThe First 4-point (4P)- MACE

The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.

Time frame:
From randomization until individual day of trial completion, up to 432 weeks
Reported as:
Number · Events/ 1000 patients-years
The First 4-point (4P)- MACE
Events/ 1000 patients-yearsLinagliptinGlimepiride
The First 4-point (4P)- MACE23.423.7
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Cox · p = 0.4334 (P-values derived from Wald´s Chi-square test for non-inferiority.) · Hazard ratio (hr): 0.99 · 95.47% CI 0.86 to 1.14Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride.
SecondaryPercentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase

The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without \>2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.

Time frame:
From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)
Reported as:
Number · Percentage of participants (%)
Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase16.0 (14.7 to 17.3)10.2 (9.1 to 11.3)
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Logistic · p = <0.0001 (p-value derived from logistic regression.) · Odds ratio (or): 1.68 · 95.47% CI 1.43 to 1.96Odds ratio and confidence interval are based on logistic regression with factor for treatment.
SecondaryPercentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase

The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without \>2% weight gain during maintenance phase.

Time frame:
From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)
Reported as:
Number · Percentage of participants (%)
Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase17.4 (16.1 to 18.8)14.1 (12.9 to 15.4)
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Logistic · p = 0.0004 (p-value derived from logistic regression.) · Odds ratio (or): 1.29 · 95.47% CI 1.11 to 1.48Odds ratio and confidence interval are based on logistic regression with factor for treatment.
SecondaryPercentage of Participants With the Occurrence of at Least One Event of 3P-MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.

Time frame:
From randomization until individual day of trial completion, up to 432 weeks
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE11.8 (10.7 to 13.0)12.0 (10.9 to 13.2)
SecondaryPercentage of Participants With the Occurrence of at Least One Event of 4P -MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.

Time frame:
From randomization until individual day of trial completion, up to 432 weeks
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE13.2 (12.0 to 14.4)13.3 (12.2 to 14.6)
SecondaryPercentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * TIA * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)

Time frame:
From start of the treatment until 7 days after the end of treatment, up to 433 weeks
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events17.1 (15.8 to 18.5)17.8 (16.4 to 19.2)
SecondaryTime to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * Transient ischaemic attack (TIA) * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)

Time frame:
From start of the treatment until 7 days after the end of treatment, up to 433 weeks
Reported as:
Number · Events/ 1000 patients-years
Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
Events/ 1000 patients-yearsLinagliptinGlimepiride
Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events31.132.4
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Cox · p = 0.5249 (p-value derived from Wald´s chi-square test.) · Hazard ratio (hr): 0.96 · 95% CI 0.85 to 1.09Hazard ratio and confidence interval derived from Cox regression with factor treatment.
SecondaryChange From Baseline to Final Visit in Hemoglobin A1c (HbA1c)

Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · Percentage glycosylated hemoglobin (%)
Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)
Percentage glycosylated hemoglobin (%)LinagliptinGlimepiride
Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)0.06 ± 0.020.15 ± 0.02
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.0023 · Mean difference (final values): -0.09 · 95% CI -0.15 to -0.03Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit in Fasting Plasma Glucose (FPG)

Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · Milligram/ deciliter (mg/dL)
Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)
Milligram/ deciliter (mg/dL)LinagliptinGlimepiride
Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)12.4 ± 0.919.7 ± 0.9
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = <0.0001 · Mean difference (final values): -7.3 · 95% CI -9.7 to -4.8Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol

Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · mg/dL
Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol
mg/dLLinagliptinGlimepiride
LDL cholesterol-6.1 ± 0.6-6.5 ± 0.6
HDL cholesterol0.7 ± 0.20.3 ± 0.2
Total cholesterol-5.4 ± 0.7-0.5 ± 0.7
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.6400 · Mean difference (final values): 0.4 · 95.47% CI -1.3 to 2.1Mean difference = Linagliptin mean - Glimepiride mean
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.0497 · Mean difference (final values): 0.5 · 95% CI 0.0 to 1.0Mean difference = Linagliptin mean - Glimepiride mean
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.6823 · Mean difference (final values): -0.4 · 95% CI -2.4 to 1.6Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit in Triglycerides

Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · mg/dL
Change From Baseline to Final Visit in Triglycerides
mg/dLLinagliptinGlimepiride
Change From Baseline to Final Visit in Triglycerides1.7 ± 2.25.2 ± 2.2
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.2678 · Mean difference (final values): -3.5 · 95% CI -9.6 to 2.7Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit in Creatinine

Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · mg/dL
Change From Baseline to Final Visit in Creatinine
mg/dLLinagliptinGlimepiride
Change From Baseline to Final Visit in Creatinine0.08 ± 0.010.09 ± 0.01
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.5165 · Mean difference (final values): -0.01 · 95% CI -0.03 to 0.01Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)

Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Least squares mean · mL/minute/1.73 meter^2
Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)
mL/minute/1.73 meter^2LinagliptinGlimepiride
Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)-4.0 ± 0.3-5.0 ± 0.3
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.5165 · Mean difference (final values): 1.0 · 95% CI 0.2 to 1.8Mean difference = Linagliptin mean - Glimepiride mean
SecondaryChange From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)

Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.

Time frame:
Baseline and week 432
Reported as:
Geometric mean · mg/ gcrea
Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)
mg/ gcreaLinagliptinGlimepiride
Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)1.52 ± 1.831.57 ± 1.83
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.2921 · Geometric mean (gmean) ratio (%): 0.97 · 95% CI 0.91 to 1.03gMean ration= Linagliptin mean/ Glimepiride mean
SecondaryPercentage of Participants With Transition in Albuminuria Classes

Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.

Time frame:
Baseline and week 432
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Transition in Albuminuria Classes
Percentage of participants (%)LinagliptinGlimepiride
Base (<30mg/gcrea) LVOT (<30mg/gcrea)58.457.7
Base(<30mg/gcrea)LVOT(>=30 to<=300mg/gcrea)14.116.0
Base (<30 mg/gcrea) LVOT (>300 mg/gcrea)1.41.4
Base (>=30 to <=300 mg/gcrea) LVOT(<30mg/gcrea)5.45.1
Base(>=30to<=300mg/gcrea)LVOT(>=30to<=300mg/gcrea)12.712.1
Base (>=30 to <=300 mg/gcrea) LVOT(>300 mg/gcrea)3.53.7
Base (>300 mg/gcrea) LVOT (<30 mg/gcrea)0.10.3
Base (>300 mg/gcrea) LVOT(>=30 to<=300mg/gcrea)0.80.9
Base (>300 mg/gcrea) LVOT(>300 mg/gcrea)3.42.7
SecondaryChange From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks

The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.

Time frame:
Baseline and week 208
Reported as:
Mean · Picomol/ minute/meter^2 (pmol/min/m²)
Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks
Picomol/ minute/meter^2 (pmol/min/m²)LinagliptinGlimepiride
Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks11.07 ± 15.076.95 ± 13.76
Statistical analysis
  • Linagliptin vs Glimepiride · ANCOVA · p = 0.8402 · Mean difference (net): 4.13 · 95% CI -36.46 to 44.71Mean difference= Linagliptin mean- Glimepiride mean
SecondaryPercentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up

Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.

Time frame:
433 weeks
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up
Percentage of participants (%)LinagliptinGlimepiride
Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up27.8 (25.6 to 30.0)27.6 (25.4 to 29.9)
Statistical analysis
  • Linagliptin vs Glimepiride · Regression, Logistic · p = 0.9112 · Odds ratio (or): 1.01 · 95% CI 0.86 to 1.18Linagliptin vs. Glimepiride odds is presented.
SecondaryContinuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.

Time frame:
Baseline
Reported as:
Mean · Milligrams/ deciliter (mg/ dL)
Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study
Milligrams/ deciliter (mg/ dL)All Participants
Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study44.2 ± 12.6
SecondaryCGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.

Time frame:
Baseline
Reported as:
Mean · Millimoles/ Litre (mmol/L)
CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study
Millimoles/ Litre (mmol/L)All Participants
CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study2.45 ± 0.7

Adverse events

Collected over From start of the treatment until 7 days after the end of treatment, up to 433 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Linagliptin308/3,023 (10.2%)1,403/3,023 (46.4%)2,376/3,023 (78.6%)
Glimepiride336/3,010 (11.2%)1,448/3,010 (48.1%)2,504/3,010 (83.2%)
Most frequent serious events
Showing 10 of 1,332
Most frequent serious events
EventLinagliptinGlimepiride
PneumoniaInfections and infestations83/302383/3010
Angina unstableCardiac disorders54/302365/3010
Myocardial infarctionCardiac disorders49/302364/3010
OsteoarthritisMusculoskeletal and connective tissue disorders49/302363/3010
Cerebrovascular accidentNervous system disorders51/302361/3010
Cardiac failureCardiac disorders58/302353/3010
Acute myocardial infarctionCardiac disorders52/302356/3010
Chest painGeneral disorders50/302352/3010
Atrial fibrillationCardiac disorders39/302348/3010
Acute kidney injuryRenal and urinary disorders47/302341/3010
Most frequent other events
Showing 10 of 25
Most frequent other events
EventLinagliptinGlimepiride
HypoglycaemiaMetabolism and nutrition disorders299/30231067/3010
NasopharyngitisInfections and infestations530/3023517/3010
HyperglycaemiaMetabolism and nutrition disorders422/3023483/3010
HypertensionVascular disorders430/3023452/3010
Back painMusculoskeletal and connective tissue disorders388/3023368/3010
DiarrhoeaGastrointestinal disorders365/3023324/3010
DizzinessNervous system disorders283/3023358/3010
BronchitisInfections and infestations315/3023340/3010
Upper respiratory tract infectionInfections and infestations313/3023319/3010
Urinary tract infectionInfections and infestations318/3023312/3010

Baseline characteristics

Treated set (TS): All patients treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)LinagliptinGlimepirideTotal
Mean63.9 ± 9.564.2 ± 9.564.0 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)LinagliptinGlimepirideTotal
Female118512292414
Male183817813619
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LinagliptinGlimepirideTotal
Hispanic or Latino5195131032
Not Hispanic or Latino249524874982
Unknown or Not Reported91019
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LinagliptinGlimepirideTotal
American Indian or Alaska Native106108214
Asian5315301061
Native Hawaiian or Other Pacific Islander538
Black or African American155169324
White221721904407
More than one race000
Unknown or Not Reported91019
08

Study locations

613 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Alabama Internal Medicine, PC
    Birmingham, Alabama 35235, United States
  • Cahaba Research, Inc.
    Birmingham, Alabama 35242, United States
  • Internal Medicine Center, LLC
    Mobile, Alabama 36608, United States
  • Diagnostic and Medical Clinic
    Mobile, Alabama 36695, United States
  • Extended Arm Physicians, Inc.
    Montgomery, Alabama 36106, United States
  • Office of Dr. Terence T. Hart MD
    Tuscumbia, Alabama 35674, United States
  • Advanced Clinical Research
    Pell City, Alaska 35128, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Mesa, Arizona 85203, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Mesa, Arizona 85213, United States
  • Genova Clinical Research
    Tucson, Arizona 85704, United States
  • Quality of Life Medical & Research Center
    Tucson, Arizona 85712, United States
  • Northeast Arkansas Baptist Clinic
    Jonesboro, Arkansas 72404, United States
  • Medical Investigations, Inc
    Little Rock, Arkansas 72205, United States
  • Aureus Research, Inc
    Little Rock, Arkansas 72211, United States
  • Desert Oasis Healthcare
    Bermuda Dunes, California 92203, United States
  • Edinger Medical Group and Research Center
    Fountain Valley, California 92708, United States
  • Clinical Trials of St. Jude Heritage Med. Group
    Fullerton, California 92835, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • Office of Dr. Richard S. Cherlin
    Los Gatos, California 95032, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Chaparral Medical Group, Inc
    Pomona, California 91767, United States
  • ARI Clinical Trials, Inc
    Redondo Beach, California 90277, United States
  • San Diego Sports Medicine and Family Health Center
    San Diego, California 92120, United States
  • West Coast Research, LLC
    San Ramon, California 94582, United States
  • University of California Los Angeles
    Sylmar, California 91342, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • Matrix Research Institute
    Tustin, California 92780, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Westlake Medical Research
    Westlake Village, California 91361, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Colorado Springs, Colorado 80909, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Colorado Springs, Colorado 80920, United States
  • East Coast Medical Associates
    Boca Raton, Florida 33433, United States
  • Todd Kazdan, DO Family Practice
    Davie, Florida 33314, United States
  • Century Clinical Research, Inc
    Daytona Beach, Florida 32117, United States
  • Doral Research Center
    Doral, Florida 33172, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Alan Graff, MD, PA
    Fort Lauderdale, Florida 33309, United States
  • M & O Clinical Research, LLC
    Fort Lauderdale, Florida 33316, United States
  • Eastern Research
    Hialeah, Florida 33013, United States
  • Research in Miami Inc
    Hialeah, Florida 33013, United States
  • Jacksonville Impotence Treatment Center
    Jacksonville, Florida 32223, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32258, United States
  • Care Partners Clinical Research LLC
    Jacksonville, Florida 32277, United States
  • Precision Clinical Research, LLC
    Lauderdale Lakes, Florida 33319, United States
  • Veritas Research Corporation
    Miami, Florida 33126, United States
  • APF Research, LLC
    Miami, Florida 33134, United States
  • Swiss Medical Research
    Miami, Florida 33135, United States
  • University of Miami
    Miami, Florida 33136, United States
  • South Miami Clinical Research
    Miami, Florida 33143, United States
  • Well Pharma Medical Research
    Miami, Florida 33143, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33155, United States
  • Kendall South Medical Center, Inc
    Miami, Florida 33185, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Advanced Research Institute, Inc
    New Port Richey, Florida 34653, United States
  • Sunshine Research Center
    Opa-locka, Florida 33054, United States
  • Diabetes and Endocrine Center of Orlando
    Orlando, Florida 32803, United States
  • Suncoast Clinical Research
    Palm Harbor, Florida 34684, United States
  • Misal Khan, MD FRCS, ED, PA
    Panama City, Florida 32401, United States
  • Iconic Clinical Trials
    Pembroke Pines, Florida 33024, United States
  • Gulf Region Clinical Research Institute
    Pensacola, Florida 32514, United States
  • St. John's Center for Clinical Research
    Ponte Vedra Beach, Florida 32081, United States
  • Metabolic Research Institute
    West Palm Beach, Florida 33401, United States
  • PMI Health Research Group
    Atlanta, Georgia 30312, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Albert F. Johary MD, PC
    Dunwoody, Georgia 30338, United States
  • Georgia Clinical Research, LLC
    Snellville, Georgia 30078, United States
  • Hayden Lake Family Physicians
    Hayden Lake, Idaho 83835, United States
  • Boise Kidney and Hypertension Institute
    Meridian, Idaho 83642, United States
  • Suburban Clinical Research
    Bolingbrook, Illinois 60490, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • John H. Stroger Jr. Hospital of Cook Country
    Chicago, Illinois 60612, United States
  • Apex Medical Research
    Chicago, Illinois 60616, United States
  • Pharmakon Inc
    Evergreen Park, Illinois 60805, United States
  • American Health Network
    Avon, Indiana 46123, United States
  • Investigators Research Group, LLC
    Brownsburg, Indiana 46112, United States
  • American Health Network of Indiana, LLC
    Franklin, Indiana 46131, United States
  • Mapleton Medical Center
    Indianapolis, Indiana 46205, United States
  • American Health Network, LLC
    Indianapolis, Indiana 46254, United States
  • McKinley Research, LLC
    Mishawaka, Indiana 46545, United States
  • American Health Network of Indiana, LLC
    Muncie, Indiana 47304, United States
  • MCM Clinical Research, LLC
    Florence, Kentucky 41042, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • Four Rivers Clinical Research, Inc
    Paducah, Kentucky 42003, United States
  • Crescent City Clinical Research
    Metairie, Louisiana 70006, United States
  • Acadia Clinical Research, LLC
    Bangor, Maine 04401, United States
  • Office of Dr. Stephen R. Smith, MD
    Baltimore, Maryland 21234, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • Tristan Medical Enterprises, PC dba Regeneris
    North Attleboro, Massachusetts 02760, United States
  • ClinSite, LLC
    Canton, Michigan 48187, United States
  • Apex Medical Research, AMR Inc
    Flint, Michigan 48504, United States
  • Westside Family Medical Center, PC
    Kalamazoo, Michigan 49009, United States
  • Tri City Medical Centers, PC
    Livonia, Michigan 48152, United States
  • KMED Research
    Saint Clair Shores, Michigan 48081, United States
  • Tri-County Research, Inc
    Sterling Heights, Michigan 48310, United States
  • Medical Research Associates
    Traverse City, Michigan 49684, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
  • Park Nicollet Institute
    Minneapolis, Minnesota 55416, United States
  • The Center for Clinical Trials, Inc.
    Biloxi, Mississippi 39531, United States

Showing the first 100 of 613 sites across 43 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Verhagen C, Janssen J, Minderhoud CA, van den Berg E, Wanner C, Passera A, Johansen OE, Biessels GJ. Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk. J Diabetes Complications. 2022 Oct;36(10):108303. doi: 10.1016/j.jdiacomp.2022.108303. Epub 2022 Aug 31. PubMed 36116359 ↗
  • Verhagen C, Janssen J, Biessels GJ, Johansen OE, Exalto LG. Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study. Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):355-364. doi: 10.1016/j.numecd.2021.10.013. Epub 2021 Oct 27. PubMed 34895804 ↗
  • Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, Espeland MA, Johansen OE. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021 Jun;64(6):1235-1245. doi: 10.1007/s00125-021-05393-8. Epub 2021 Feb 9. PubMed 33559704 ↗
  • Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772. Erratum In: JAMA. 2019 Dec 3;322(21):2138. doi: 10.1001/jama.2019.19012. PubMed 31536101 ↗
  • Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ. HbA1c, Insulin Resistance, and beta-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy. Diabetes Care. 2019 Jan;42(1):e1-e3. doi: 10.2337/DC18-0914. No abstract available. PubMed 30811335 ↗
  • Biessels GJ, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE; CAROLINA(R) investigators. Rationale and design of the CAROLINA(R) - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. BMC Neurol. 2018 Jan 15;18(1):7. doi: 10.1186/s12883-018-1014-7. PubMed 29334906 ↗
  • Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res. 2015 May;12(3):164-74. doi: 10.1177/1479164115570301. Epub 2015 Mar 15. PubMed 25780262 ↗
  • Chilton R. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2013 Jul;8(4):345-349. doi: 10.1586/17446651.2013.811849. PubMed 30736150 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Aug 2018, 93 months.

Results were first posted in Jan 2020, 1 year 4 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 93 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 18, 2010
StartActual
Nov 11, 2010
Primary completionActual
Aug 21, 2018
CompletionActual
Aug 21, 2018
Results first posted
Jan 7, 2020
Last update
Jan 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01243424
Responsible party
Sponsor
First posted
Nov 18, 2010
Start date
Nov 11, 2010
Primary completion
Aug 21, 2018
Completion
Aug 21, 2018
Results posted
Jan 7, 2020
Last update
Jan 7, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion